While 25% of human cancers harbor oncogenic Ras mutations, such mutations are not found in astrocytomas. We have previously demonstrated that the activation of receptor tyrosine kinases expressed by malignant human astrocytoma cells and specimens results in functional upregulation of the Ras signalling pathway and increased levels of activated Ras.GTP. Farnesyl transferase inhibitors (FTIs) are promising anti-cancer agents in early clinical trials, which may exert their eect through pharmacological inhibition of the Ras signalling pathway. In this study we establish the anti-tumorigenic properties of the FTI L-744,832 against a panel of malignant human astrocytoma cell lines. Furthermore, we demonstrate the multiple mechanisms by which L-744,832 exerts its eect. L-744,832 demonstrates both cytostatic and cytotoxic eects on astrocytoma cells, and cells expressing a truncated constitutively phosphorylated Epidermal Growth Factor Receptor common in highgrade astrocytomas (EGFRvIII/p140
While 25% of human cancers harbor oncogenic Ras mutations, such mutations are not found in astrocytomas. We have previously demonstrated that the activation of receptor tyrosine kinases expressed by malignant human astrocytoma cells and specimens results in functional upregulation of the Ras signalling pathway and increased levels of activated Ras.GTP. Farnesyl transferase inhibitors (FTIs) are promising anti-cancer agents in early clinical trials, which may exert their eect through pharmacological inhibition of the Ras signalling pathway. In this study we establish the anti-tumorigenic properties of the FTI L-744,832 against a panel of malignant human astrocytoma cell lines. Furthermore, we demonstrate the multiple mechanisms by which L-744,832 exerts its eect. L-744,832 demonstrates both cytostatic and cytotoxic eects on astrocytoma cells, and cells expressing a truncated constitutively phosphorylated Epidermal Growth Factor Receptor common in highgrade astrocytomas (EGFRvIII/p140
EGF-R ) demonstrate increased sensitivity to the agent. L-744,832 is capable of inducing apoptosis in astrocytoma cells under anchoragedependent conditions; this process occurs in a p53-independent manner and is associated with increased expression of Bax and Bak. L-744,832 also induces cell cycle arrest at both the G 1 /M and G 2 /S checkpoints; this process is also independent of p53 mutational status. Cell cycle arrest in drug-treated cells can be accompanied by induction of p21 WAF1/CIP1 , but this induction is not necessary for the cell cycle inhibitory eects, nor is it dependent on functional p53. Finally, angiogenesis in astrocytomas has been shown to be dependent on secretion of Vascular Endothelial Growth Factor (VEGF) by tumour cells, particularly under hypoxic conditions. L-744,832 potently inhibits the secretion of VEGF under hypoxic conditions. These combinations of mechanisms suggest that these tumours, despite theIntroduction Point mutations involving the 21 kDa intracellular protein Ras have been identi®ed in approximately 25% of human malignancies (Bos, 1989) . Ras is a guanine nucleotide-binding protein, functionally similar to the a subunit of heterotrimeric G-proteins. In its GTP-bound form, Ras is activated, resulting in the downstream activation of numerous signal transduction pathways. Ras.GTP is rapidly inactivated to Ras.GDP through an intrinsic GTPase activity, catalyzed by GTPase Activating Proteins (Ras-GAPs), predominantly p120-GAP and neuro®bromin, the protein product of the NF1 gene (Downward, 1992; Xu et al., 1990) . Oncogenic Ras is resistant to RasGAPs (Barbacid, 1987) , and is thus locked in its GTPbound form, resulting in constitutive activation of the protein and persistent activation of downstream pathways.
Oncogenic Ras mutations have been identi®ed in a wide variety of human malignancies, notably in 50% of colon and 90% of pancreas carcinomas (Bos, 1989) , and such mutations have been shown to provide Ras with potent oncogenic potential (Smith et al., 1986) . Oncogenic Ras mutations have not been discovered in human astrocytomas (Bos, 1989; Tuzi et al., 1991) , which constitute the most common primary malignancy involving the central nervous system (Zimmerman, 1969) . However, it has been demonstrated that high grade (grade IV) astrocytomas, known as glioblastoma multiforme (GBM), express high levels of ligand-dependent and -independent growth factor receptors (Fleming et al., 1992; Guha et al., 1995a; Libermann et al., 1984; NisteÂ r et al., 1988; Steck et al., 1988; Sugawa et al., 1990; Wong et al., 1992) which are functionally relevant for tumour growth (Guha et al., 1995a,b; Shamah et al., 1993) . We have demonstrated these various receptors to result in a functional activation of the Ras pathway in a wide range of astrocytoma cell lines (U87, U118, U138, U343 and U373-MG cells). Levels of activation Ras.GTP were considerably higher in these cells than in normal foetal human astrocytes or murine ®broblasts (NIH3T3 cells), but were similar to levels in v-H-Ras transformed murine ®broblasts (RT8 cells) (Guha et al., 1997) . Furthermore, we demonstrated levels of activated Ras.GTP also to be elevated in human GBM tumour specimens compared to normal brain specimens (Guha, et al., 1997) . Ras activation in astrocytomas is not on the basis of inadequate Ras-GAP activity, since abundant levels of both p120-GAP and neuro®bromin, the two major mammalian Ras-GAPs, are found in these tumours (Gutmann et al., 1996) . Transfection of the dominant inhibitory mutant H-Ras N17 (Feig and Cooper, 1988) to reduce Ras.GTP levels resulted in reduced anchorage-dependent proliferation and colony formation in soft agar (Guha, et al., 1997) . These previous experiments therefore establish the functional relevance of Ras pathway activation in human astrocytomas and GBMs.
The recognition that oncogenic Ras mutations are common in human malignancies has led to signi®cant interest in the development of pharmacologic agents to inhibit the Ras pathway. In particular, farnesyl transferase inhibitors (FTIs) inhibit the ®rst step in the post-translational modi®cation of Ras and other farnesylated intracellular proteins. This step, catalyzed by protein farnesyl transferase (FPTase) involves the transfer of a 15-carbon, trans,trans-farnesyl moiety from farnesyl pyrophosphate (FPP) to the cysteine residue on the CAAX (C=cysteine, A=aliphatic amino acid, X=any other amino acid) motif at the C-terminal of Ras. This ®rst step is absolutely essential for Ras functioning, while subsequent steps (cleavage of the terminal three AAX peptides, carboxyl-methylation of the now C-terminal, farnesylated cysteine residue and optional palmitoylation at cysteine residues upstream of the C-terminal cysteine) are not critical for Ras functioning (Hancock et al., 1990) . Although many other cellular proteins in addition to Ras are farnesylated, no mechanism-related adverse eects have been noted with experimental use of these agents in cell culture and animal models Norgaard et al., 1999) . As FTIs inhibit the post-translational modi®cation of Ras, they are presumed to inhibit eector pathways downstream of Ras. This includes both the mitogenic Ras-Raf-MAPK cascade, resulting in reduced cellular proliferation, as well as the Rho-Rac pathway, resulting in altered cellular morphology (Prendergast et al., 1994 .
Although initially intended to inhibit the proliferation of tumours in which oncogenic Ras mutations resulted in persistent elevations in Ras.GTP levels, there is growing evidence that such agents also inhibit the proliferation of human cancer cell lines lacking oncogenic Ras mutations (Nagasu et al., 1995; SeppLorenzino et al., 1995) . Our previous work has demonstrated a role for Ras activation in GBMs as noted above (Guha et al., 1997) . In the current paper, we demonstrate the growth-inhibitory eect of the FTI L-744,832 on a panel of ®ve established astrocytoma cell lines. In particular, this paper demonstrates the dual eect of this agent, being both cytostatic at lower doses and cytotoxic at higher doses. L-744,832 is able to induce apoptosis in these cells even under anchorage-dependent conditions, a process which is associated with increased levels of the pro-apoptotic proteins Bax and Bak in the absence of changes in Bcl-X L expression. Furthermore, L-744,832 inhibits cell cycle progression in these cell lines in a p53-independent manner, inhibiting progression through both the G 1 /S and G 2 /M checkpoints. Finally, we demonstrate the potential anti-angiogenic role of FTIs, through inhibition of secretion of the potent angiogenic factor Vascular Endothelial Growth Factor (VEGF).
Results

Growth inhibition of astrocytoma cells by L-744,832
The IC 50 for each cell line treated with L-744,832 is depicted in Figure 1 . The IC 50 for established human astrocytoma cell lines ranged from 5.3 mM (for U138 cells) to 17.4 mM (for U343 cells). Intermediate IC 50 values included U118 (11.2 mM), U373 (13.9 mM) and U87 cells (14.9 mM). Proliferation of U118:p140 EGF-R astrocytoma cells, which express the constitutively phosphorylated truncated (140 kDa) EGF-R commonly expressed in GBMs (Ekstrand et al., 1994) , was more readily inhibited compared to mock-transfected U118 cells, which express only the wild type EGF-R. The IC 50 for L-744,832 for U118 cells (11.2 mM; 95% con®dence interval 10.3 ± 12.3 mM) was signi®cantly higher than for U118:p140 EGF-R cells (4.4 mM; 95% con®dence interval 3.7 ± 5.1 mM). This dierence reaches statistical signi®cance as the 95% con®dence intervals for these two cell lines do not overlap.
As depicted in Figure 2 , L-744,832 demonstrates both cytostatic as well as cytotoxic activity. L-744,832 demonstrates a predominantly cytostatic eect on U87 cells at 20 mM. This cytostatic eect was maintained throughout the duration of drug therapy, but was largely reversible upon discontinuation of drug therapy on day 8. At 50 mM, however, U87 cells were rapidly killed upon exposure to the agent. These eects were grossly visible using Trypan blue exclusion, resulting in a substantial reduction in cell number within 24 h, Figure 3 . The cytotoxic eect of 50 mM L-744,832 was not reversible upon discontinuation of drug treatment.
The dose-dependent eects demonstrated by this agent are accompanied by progressive inhibition of Ras processing and membrane localization on S-100/P-100 fractionation experiments. In these fractionation experiments, 50 mM essentially abolished the faster-migrating band representing fully-processed Ras, Figure 4 .
FTIs inhibit activation of MAPK in a cell line-dependent manner
One of the major mitogenic signalling pathways downstream of Ras involves the serial activation of protein kinases in the Mitogen Activated Protein Kinase (MAPK) pathway. Activated (phosphorylated) MAPK translocates to the nucleus, where it phosphorylates and activates nuclear transcription factors (notably jun and fos) (Dent et al., 1992; Howe et al., 1992; Kyriakis et al., 1992; Marshall, 1995 Figure 2 Mean+standard error of the mean (s.e.m.) of cell counts for U87 cells grown in 10% serum and treated with L-744,832 (20 or 50 mM) or vehicle alone (0.1% methanol). Twelve thousand ®ve hundred cells were plated in 24-well plates, and drug treatment undertaken from days 3 ± 8. Viable cells were counted using Trypan blue exclusion using a hemocytometer. 20 mM L-744,832 demonstrates a partially reversible cytostatic eect on U87 cells, while 50 mM demonstrates a non-reversible cytotoxic eect on these cells. This cytotoxicity is largely mediated through enhanced apoptosis (see Figure 7) Figure 3 Morphologic characteristics of U373 cells treated with vehicle or 50 mM L-744,832. Cells were treated with the agent for 3 days prior to ®xation and staining for GFAP. A subset of vehicle-treated U373 cells stains positive for GFAP, including large cells with abundant cytoplasm (large arrow) and small cells (small arrow). Most vehicle-treated cells are GFAP-negative. L-744,832 resulted in a generalized increase in cytoplasm in all cells, with rounding of cell bodies. In addition, many cells developed long astrocytic processes, which were largely GFAP-negative Figure 4 Demonstration that L-744,832 mediates its Rasinhibitory eect through a dose-dependent reduction in Ras processing and membrane localization. Membrane (P-100) and soluble (S-100) fractions were obtained from drug treated cells, and Ras immunoprecipitated using the anti-pan-Ras antibody Y13-259. Ras was visualized on Western blots using the anti-panRas antibody OP40 (Oncogene Science). Note loss of the processed Ras bands in the 50 mM drug treatment lanes Figure 5 Determination of ERK1/2 MAPK kinase activity in drug-treated U373 and U138 cells. L-744,832 elicits only a modest reduction in MAPK kinase activity in U138 cells, despite the sensitivity of these cells to growth-inhibition by the agent (see Figure 1 ). In contrast, U373 cells treated with 40 mM L-744,832 demonstrate a 65% reduction in MAPK activity in the MBP kinase assay. Radio-labelled MBP was separated on a SDS ± PAGE gel (b) and kinase activity quanti®ed on a PhosphoImager (a) eect, at least in part, through a dual eect on cell cycle progression. Even 20 mM L-744,832 results in a substantial reduction in BrdU incorporation in both U87 and U373 cells, Table 1 and Figure 6 (P50.05 by Factorial ANOVA). This eect was only slightly greater in cells treated with 50 mM L-744,832. The eect of L-744,832 on BrdU incorporation suggests an inhibitory eect on cell cycle progression through the G 1 /S checkpoint, and this eect is apparent even at moderate drug doses (20 mM). Furthermore, L-744,832 demonstrates an inhibitory eect on cell cycle progression through the G 2 /M checkpoint, with a dose-dependent increase in the G 2 /M fraction in both U87 and U373 cells (P50.05 for U87 at 50 mM and for U373 at 20 and 50 mM), Table 1 and Figure 6 . The pattern of these eects are comparable in U87 cells (wild type p53) and U373 cells (mutant pP53), implicating p53-independent mechanisms for both the G 1 /S and G 2 /M cell cycle blocks.
Induction of apoptosis by L-744,832
Apoptosis was assayed using the Terminal deoxynucleotidyl transferase-mediated dUTP Nick End Labelling (TUNEL) assay (Gavrieli et al., 1992) , Figure 7 . Consistent with the proliferation curve in Figure 2 , moderate doses of L-744,832 (20 mM) caused only a moderate increase in apoptosis. At 20 mM L-744,832, U87 cells saw the rate of apoptosis increase from 0.9+0.3% to 7.9+0.8% (P=0.003), while U373 cells saw an increase from 1.7+0.1% to 6.3+1.1% (P=0.103). At 50 mM L-744,832, however, both U87 and U373 cells saw a substantial increase in the rate of apoptosis, with a labelling index of 20.4+1.6% for U87 cells and an index of 22.9+2.9% for U373 cells (P50.0001 for both cell lines, compared both to 20 mM and vehicle-treated groups). We maximized our ability to detect apoptotic cells by pre-coating the Lab-Tek chamber slides with 0.01% poly-L-lysine. Despite this coating, these labelling indices likely underestimate the substantial rate of apoptosis in cells treated with 50 mM L-744,832, as the agent demonstrates a rapid cytotoxic eect, Figure 2 .
Cellular mechanisms for induction of apoptosis and for cell cycle eect
In order to further elucidate the mechanisms by which L-744,832 elicits its eect on apoptosis and cell cycle progression, we evaluated levels of speci®c relevant proteins in lysates of vehicle and drug treated cells. U87 cells (wild type for p53) and U373 cells (mutant p53) were again chosen in order to evaluate the eect of p53 mutational status on these proteins. L-744,832 increases the expression of the pro-apoptotic proteins Bax and Bak in both U87 and U373 cells, while there is little change in the expression pro®le for the antiapoptotic protein Bcl-X L , Figure 8a . Surprisingly however, the agent also appears to potently increase expression of the anti-apoptotic protein Bcl-2.
U373 cells demonstrate robust expression for p53, due to the presence of a point mutation in the protein resulting in enhanced protein stability. U87 cells demonstrate only a weak signal for p53 due to their wild type status for this protein. L-744,832 did not change the levels of p53. This agent did however result in reduced expression of pRb and reduced expression of the hyperphosphorylated form of pRb, notably in U373 cells. Due to the eect of L-744,832 on both G 1 /S and G 2 /M checkpoints, and its p53-independent eects, we evaluated the eect of the agent on expression of the cyclin dependent kinase inhibitor p21
. While the agent had little eect on p21 expression in U87 cells, 50 mM L-744,832 potently induced expression of p21 in U373 cells. This thus suggests that FTIs are capable of inducing p21 expression in a p53-independent manner in human cell lines. All Western blot experiments were carried out at least twice, and representative blots are shown in Figure 8 . Equal protein loading was con®rmed by reprobing for b-actin ( Figure 8c ).
Morphological changes in cells treated with FTIs
In addition to their eect on proliferation, we evaluated the eect of L-744,832 on the morphology of astrocytoma cells in culture. Cells subjected to the vehicle (0.1% methanol) do not demonstrate any altered morphology compared to cells treated with DMEM alone. However, cells grown in either 20 or 50 mM L-744,832 demonstrate a marked dose-dependent change in their morphologic phenotype. Cells became larger, more rounded, and less refractile. In addition, drug-treated cells were contact-inhibited, forming a single layer of cells rather than the overlapping meshwork of cells seen in vehicle-treated astrocytoma cells. Similar eects were seen in all the cell lines tested. U373 cells in particular demonstrated a pattern of process formation suggestive of astrocytic dierentiation, Figure 3 . While astrocytic differentiation is marked by positive staining for Glial Fibrillary Acidic Protein (GFAP), we did not see a change in GFAP positivity in cells treated with L-744,832. U87 cells are GFAP negative, and L-744,832 did not induce GFAP expression in these cells. Only a subset of U373 cells is GFAP positive, and those cells demonstrating the most marked morphological changes in response to L-744,832 did not express GFAP. GFAP was not detected in the long astrocytic processes of drug-treated cells. Eect on expression and secretion of VEGF VEGF levels were measured in the conditioned medium of U373 cells treated with L-744,832 using a quantitative ELISA kit, and con®rmed using metabolic labelling studies. Equal cell numbers were plated at the start of the experiment, and conditioned medium was harvested following 4 days of drug treatment, including 24 h of growth under either normoxic or hypoxic conditions. L-744,832 had little eect on levels of VEGF in the conditioned medium of drug-treated cells grown under normoxic conditions (Figure 9a,b) . However, the agent demonstrates a dramatic inhibitory eect on the hypoxic induction of VEGF in these cells. We evaluated the eect of L-744,832 on U373 cells, which we have previously shown to demonstrate Figure 6 Composite ®gure demonstrating the eect of L-744,832 on cell cycle progression and BrdU incorporation in U87 cells (wild type p53) and U373 cells (mutant p53). Both cells were similarly aected, suggesting a p53-independent mechanism. L-744,832 results in a dose-dependent increase in the proportion of cells in the G 2 /M fraction of the cycle, as well as a reduction in BrdU incorporation. Numeric data is provided in Table 1 robust hypoxic induction of both VEGF mRNA and protein (Feldkamp et al., 1999) . While the levels of VEGF mRNA were minimally aected by exposure to the agent (Figure 9d ), levels of secreted protein were signi®cantly reduced in cells grown in as little as 10 mM drug. These dierences were statistically signi®cant both when total secreted VEGF was evaluated ( Figure  9a ), or when VEGF levels were normalized to cell counts (Figure 9b ; P50.05 by Factorial ANOVA). Hypoxia increased VEGF levels approximately fourfold in vehicle-treated cells (59.8 vs 14.7 ng/mL/10 6 cells), while VEGF levels only increased by 24% under hypoxic conditions when pre-treated with 10 mM L-744,832. This translates to a 64% reduction in normalized VEGF levels with 10 mM (59.8 vs 21.7 ng/ mL/10 6 cells). We con®rmed the eect of L-744,832 on VEGF secretion using metabolic labelling with 35 Smethionine (Figure 9c ). 20 mM L-744,832 reduced the intensity of immunoprecipitated bands appreciably, demonstrating a reduction in levels of newly-synthesized VEGF secreted into the conditioned medium. The speci®city of these bands was con®rmed using peptide competition studies (Figure 9c , lane 3).
Discussion
Point mutations involving codons 12, 13 and 61 of Hand K-Ras have been identi®ed in approximately 25% of human malignancies (Bos, 1989; Smith et al., 1986) , although such oncogenic mutations have not been discovered in astrocytoma tumour specimens (Bos 1989; Tuzi et al., 1991) or in the established malignant human astrocytoma cell lines which we have previously characterized (U87, U118, U138, U343 and U373-MG cell lines) (Guha et al., 1997) . Previous reports have demonstrated that high-grade astrocytomas (GBMs) are characterized by ampli®cation and rearrangement of the EGF-R gene (Ekstrand et al., 1994; Libermann, et al., 1984; Steck et al., 1988; Sugawa et al., 1990; Wong et al., 1992) , and overexpression of the PDGFRa and PDGFR-b receptors and their ligands (PDGF-A and PDGF-B), which are also functionally important in the molecular pathogenesis of these high-grade malignancies (Guha et al., 1995a,b; Shamah et al., 1993) . Activated EGF-R and PDGF-R in astrocytoma cell lines associate with the signalling proteins Shc and GRB2, recruiting the nucleotide exchange factor mSos in proximity to the cell surface (Guha et al., 1997; Rozakis-Adcock et al., 1993) , where it can exchange Ras-bound GDP for GTP resulting in activation of Ras. We have also demonstrated, using a novel enzymatic assay, that high levels of activated Ras.GTP are not only present in the astrocytoma cell lines, but also in human operative tumour specimens (Guha et al., 1997) . Therefore astrocytomas demonstrate activation of Ras, functionally similar to Ras-transformed human tumours, in which the protein is locked in its GTP-bound form (Barbacid, 1987) .
Numerous investigators have pursued pharmacological means by which to inhibit Ras in the face of oncogenic mutations, notably by inhibiting the posttranslational modi®cation of Ras. Inhibition of the ®rst of these steps (farnesylation of the cysteine residue of the C-terminal CAAX motif) results in the accumulation of Ras-Raf complexes in the cytosol which are not able to interact with the signalling machinery at the cell surface (Lerner et al., 1995a; Miyake et al., 1996) . Although originally conceived for tumours harbouring oncogenic mutations of Ras, we hypothesized that FTIs would also be of use in human tumours such as astrocytomas, in which Ras is functionally activated though otherwise normal. In this paper, we have proceeded to investigate the feasibility of inhibiting the growth of astrocytoma cells in culture using the FTI L-744,832.
All ®ve established human malignant astrocytoma cell lines (U87, U118, U138, U343 and U373) were , 1995) . The IC 50 doses for our cell lines are however clearly higher than has been demonstrated for H-Rastransformed ®broblasts (Kohl et al., 1993 . FTIs preferentially inhibit the proliferation of H-Ras transformed cells, with K-Ras transformed cells either being resistant to these agents or being inhibited at higher drug doses (James et al., 1996; Lerner et al., 1995b; Manne et al., 1995; Nagasu et al., 1995; Zhang et al., 1997) . This relative resistance of K-Rastransformed cell lines to FTIs is due to the observation that K-Ras and (to a lesser extent) NRas, but not H-Ras, can be post-translationally modi®ed by geranylgeranyltransferase I (GGTase I) (Lerner et al., 1995b; Whyte et al., 1997) , a related enzyme which transfers a 20-carbon prenyl group from geranylgeranyl pyrophosphate to cysteine residues in proteins. Cells lacking oncogenic Ras mutations can be inhibited by FTIs, but these eects, as in our cells, occur at higher drug doses than for H-, N-, or K-Ras transformed cells (Nagasu et al., 1995) . Our results thus contribute to previous observations that cancer cell lines can be growth-inhibited by FTIs regardless of Ras mutational status (Sepp-Lorenzino et al., 1995) .
The mechanism by which FTIs confer their antitumorigenic eect was initially presumed to be on the basis of Ras pathway inhibition. For this reason, we evaluated the eect of L-744,832 on activation of the Ras-Raf-MAPK pathway. We evaluated ERK1/2 MAPK kinase activity in U138 cells (our most sensitive cell line) and U373 cells (relatively resistant cell line). ERK1/2 activity was minimally aected in U138 cells, despite their sensitivity to the agent, while U373 cells demonstrated marked inhibition of MAPK activity, Figure 5 . These results suggest either that absolute levels of MAPK are not predictive of the proliferative potential of cells, or that other pathways may be more important in mediating mitogenic signalling in U138 cells. Evidence to support the latter observation come from our studies using the dominant inhibitory mutant H-Ras N17 (Guha et al., 1997) ; H-Ras N17 potently inhibits the proliferation of U373 cells, with corresponding reductions in ERK1/2 kinase activity, while it appears to exert little eect in many other astrocytoma cell lines (A Guha, unpublished observations). Furthermore, a recent paper has demonstrated that FTIs inhibit p70 s6K , a Ras-dependent but not MAPK-dependent kinase .
Our results clearly demonstrate a dual cytostatic and cytotoxic eect in astrocytoma cells, depending on drug dosage, Figure 2 . The cytostatic eects of the drug relate predominantly to inhibition of cell cycle progression at both the G 1 /S and G 2 /M checkpoints, Figure 7 . These eects occur in both U87 cells (wildtype for p53) and U373 cells (mutant p53), indicating that the cell cycle eects in these cells occur independently of p53 function. While it has been suggested that G 1 /S progression is dependent on geranylgeranylation in some cells (Vogt et al., 1996) , further studies have demonstrated that FTIs induce a p53-dependent G 1 /S block in a subset of treated cells, and can also induce cell cycle arrest in both G 1 and G 2 , but always in a p53-dependent manner (SeppLorenzino and Rosen, 1998). These published results, when compared to our own results, clearly demonstrate that cell speci®city plays an important role in determining the mechanism of FTI eect. At the very least, our results con®rm that L-744,832 can induce both G 1 /S and G 2 /M cell cycle arrest, but in contrast to previously published reports demonstrate that this can occur in a p53-independent manner.
We have evaluated whether p21 WAF1/CIP1 induction plays a role in this dual eect on cell cycle progression. p21 expression was unaltered in drug-treated U87 cells, demonstrating that p21 induction is not required for the cell cycle eects of this agent. However, U373 cells treated with 50 mM L-744,832 consistently demonstrate strong p21 induction, Figure 8 . In contrast to previous studies, this suggests that the induction of p21 by speci®c inhibitors of farnesyl transferase is not dependent on functional p53 (Sepp-Lorenzino and Rosen, 1998). As demonstrated in Figure 2 , these cytostatic eects are largely reversible upon discontinuation of the agent. FTIs have been noted to induce apoptosis in cells under anchorage-independent conditions (Barrington et al., 1998; Lebowitz et al., 1997a) . All of our apoptosis assays were performed under anchoragedependent conditions, using culture plates pre-coated with poly-L-lysine to increase cell adhesion, Figure  7 . Furthermore, our results con®rm that FTI-induced apoptosis is not dependent on functional p53 (Lebowitz et al., 1997a) . While overexpression of the anti-apoptotic protein Bcl-X L has been shown to block the induction of apoptosis by FTIs in ®broblasts, there have been no previous studies evaluating the eect of these agents on the expression of Bcl-2 family proteins. Figure 8 demonstrates that FTIs induce expression of the pro-apoptotic proteins Bax and Bak, in the absence of changes in Bcl-X L expression. While this alone could account for the apoptotic eects of the agent, treatment with this agent also potently induces the expression of the anti-apoptotic protein Bcl-2. Although the ratio of Bax to Bcl-2 appears to help determine the ultimate fate of cells (Gross et al., 1998) , it is also clear that Bcl-2 and Bax can function independently in regulating cell death (Knudson and Korsmeyer, 1997) . Finally, further studies will be needed to determine the functional role of these proteins, as post-translational modifications such as phosphorylation are important in modulating the role of these proteins in apoptosis (Scatena et al., 1998) .
Despite our rational approach to targeting activated Ras in these cells, we cannot provide compelling evidence that Ras is the only substrate inhibited by the agent in our studies. Indeed, a number of results would suggest that Ras is not the only target in these cells. Firstly, cellular fractionation experiments demonstrate clear inhibition of Ras processing at 50 mM, but do not demonstrate much eect at 20 mM (Figure 4) , despite the fact that this same 20 mM dose is well above the IC 50 for most cell lines. Furthermore, cell death is induced very rapidly, yielding a dramatic reduction in cell viability within 24 h for cells treated with 50 mM L-744,832 ( Figure  2) ; such a rapid eect cannot be explained by inhibition of post-translational modi®cation of Ras. Finally, we have demonstrated dramatic eects of this agent on cellular morphology (Figure 3 ). While this eect on the cytoskeletal architecture could still be mediated by Ras, through the eects of Ras on the small GTPases Rho and Rac (Prendergast and Gibbs, 1993; Ridley et al., 1992) , it is equally clear that FTIs can directly inhibit the farnesylation of RhoB (Du et al., 1999; Lebowitz et al., 1995 Lebowitz et al., ,1997b . Furthermore, recent evidence demonstrate cooperative signalling Figure 9 Eect of L-744,832 on VEGF mRNA levels (d) and secreted protein levels in conditioned medium (a ± c). Levels of secreted VEGF were determined using a quantitative ELISA kit (R&D Systems). L-744,832 had little eect on VEGF levels under normoxic conditions, but substantially reduced VEGF levels under hypoxic conditions. The total reduction in VEGF (a) was still signi®cant when levels were expressed as a function of the number of cells on the plate, in order to account for the anti-proliferative eect of the drug (b). This reduction in secreted VEGF was con®rmed using metabolic labelling with 35 S-methionine (c), demonstrating a reduction in secreted newly-synthesized VEGF. The speci®city of the immunoprecipitated protein bands was con®rmed using peptide competition studies (lane 3, c). L-744,832 did not appear to have a signi®cant eect on the hypoxic induction of VEGF mRNA (d) between Ras and Rho in regulating p21 expression (Izawa et al., 1996; Olson et al., 1998) . These results taken together suggest multiple targets for FTIs in these cells.
Previous papers have reported that L-744,832 can elicit a marked anti-tumorigenic eect in vivo, somewhat out of keeping with its more moderate anti-proliferative eects in vitro . We thus investigated whether this enhanced in vivo eect may relate to an additional anti-angiogenic eect of the agent. Evidence from our laboratory and from others has demonstrated the importance of the angiogenic factor Vascular Endothelial Growth Factor (VEGF) in the pathogenesis of high grade astrocytic tumours (Asano et al., 1995; Feldkamp et al., 1999; Melnyk et al., 1996; Millauer et al., 1996; Saleh et al., 1996) . Astrocytomas secrete high levels of the potent and endothelial speci®c angiogenic factor VEGF (Plate et al., 1992) , whose expression through increased transcription or enhanced mRNA stability is highly regulated by hypoxia Goldberg and Schneider, 1994; Levy et al., 1996) . Ras appears to play a pivotal role in regulating the secretion of VEGF, as expression of oncogenic Ras induces VEGF expression in NIH3T3 (Grugel et al., 1995) and non-tumorigenic intestinal epithelial cells (Rak et al., 1995) . We therefore investigated whether FTIs have an additional antiangiogenic role through inhibition of VEGF secretion, under either normoxic or hypoxic conditions. Our results demonstrate that L-744,832 does possess an additional anti-angiogenic eect, by reducing the amount of VEGF secreted by astrocytoma cells. This eect was most notable under hypoxic conditions, and occurred with relatively low doses of L-744,832. Pre-treatment of cells for 3 days with only 10 mM L-744,832 reduced VEGF in the conditioned medium of cells by 64% (levels normalized to level per 10 6 cells), Figure 9b . This reduction in secreted VEGF was con®rmed using metabolic labelling and immunoprecipitation of VEGF from the conditioned medium, Figure 9c . The reduction in levels of VEGF in the conditioned medium did not appear to be the result of altered mRNA levels, Figure 9d , suggesting that FTIs regulate VEGF levels either at the translational level or by inhibiting the exocytosis of this protein.
Our experiments therefore demonstrate that the proliferation of a wide range of human malignant astrocytoma cell lines can be inhibited using the FTI L-744,832. The mechanisms by which FTIs inhibit astrocytoma cell growth likely include but are not limited to inhibition of post-translational modi®cation of Ras. L-744,832 mediates its eects in astrocytomas through a combination of eects on proliferation, cell cycle progression, apoptosis, and likely also angiogenesis. FTIs thus could be predicted to possess greater anti-tumorigenic eects in vivo than in vitro, by combining their anti-proliferative eects with antiangiogenic eects, as mediated by decreasing VEGF secretion. The combination of these various mechanisms suggests that FTIs may be promising agents in the management of these presently terminal human brain tumours, and adds high grade glial tumours as a further indication for further clinical trials involving FTIs.
Materials and methods
Cell lines and culture conditions
Six stable human malignant astrocytoma cell lines were utilized in these studies. U373 and U-343Cl2:6 cells were a gift of B Westermark (Uppsala, Sweden). U138 and U87 cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA). U118 and U118:p140 EGF-R cell lines were a gift of C David James (Mayo Clinic, Rochester, MN, USA). p140
EGF-R cells represent U118 cells transfected to stably express a truncated (140 kDa) constitutively activated EGF-R commonly expressed by malignant human astrocytomas, under the control of a constitutive SV40 promoter (Ekstrand et al., 1994) . All cells were grown at 378C in a 5% CO 2 incubator in Dulbecco's Modi®ed Essential Medium (DMEM) supplemented with 10% calf serum. p140
EGF-R cells were maintained in medium supplemented with 200 mM methotrexate and 200 mg/mL G418. We have previously demonstrated the absence of activating mutations involving either H-or K-Ras in these cell lines (Guha et al., 1997) .
Proliferation curves and determination of IC 50 for L-744,832
The FTI L-744,832 was obtained from Merck Research Laboratories (gift of Allen Oli, West Point, PA, USA), and was stored in a 50 mM stock solution in 50% methanol at 7208C. Dose-response curves were determined for each of the six astrocytoma cell lines (U87, U118, P140 EGF-R , U138, U343, U373) by modelling a log normal dose-response relationship. Logistic regression (probit analysis) was used to estimate the IC 50 for each cell line, de®ned as the dose at which the number of cells was reduced to 50% of control wells (SAS version 6.12, SAS Institute Inc., Cary, NC, USA), Figure 1 . One thousand cells were plated in 96-well plates and treated with L-744,832 at doses between 0.01 mM and 100 mM; control cells were grown in medium alone or in medium supplemented with the vehicle. The vehicle concentration was kept constant (0.1% methanol) in all treatment wells. Each experiment was repeated three times in triplicate. Cell viability was measured using the Cell Titre 96 AQueous One Solution kit (Promega, Madison, WI, USA). This assay determines cell viability using the tetrazolium compound, MTS (Owen's reagent), which is bioreduced by viable cells into a coloured formazan product (Goodwin et al., 1995) . Following drug treatment for 14 days, viability was determined by adding 100 ml of fresh medium and 7.5 ml of MTS solution to each well. Plates were incubated at 378C for 1 h, and plates read on an enzyme-linked immunosorbent assay (ELISA) plate reader at a wavelength of 490 nm, subtracting reference readings at a wavelength of 630 nm. The absorbance for each dose was compared to that in wells treated with medium alone, and expressed as a fraction of control proliferation.
Two dosage levels were selected for additional proliferation assays of U87 cells under anchorage-dependent conditions, Figure 2 . Twenty mM was chosen to re¯ect a dose close to the IC 50 of most cell lines, while 50 mM was chosen as a dose near the IC 95 level for most cell lines. 12 500 U87 cells were plated in 24-well plates, and drug treatment was commenced on day 3. Cells were grown in the presence of L-744,832 (or vehicle alone) for 5 days, with drug being replenished after 3 days. On day 8, cells were washed three times with PBS to remove traces of the drug or vehicle. Cells were subsequently grown in regular medium until day 14. All experiments were performed in duplicate wells, and the entire experiment repeated twice. Viable cells were counted using Trypan blue exclusion using a hemocytometer.
Ras processing assay
To con®rm the eectiveness of L-744,832 in preventing the post-translational processing and membrane localization of Ras in these cells, we performed S-100/P-100 fractionation experiments. Following 3 days of treatment with L-744,832 (20 and 50 mM) or with vehicle (0.1% methanol), cells were trypsinized, pelleted, and lysed in Lysis Buer A (10 mM Tris.HCl pH 7.5, 10% sucrose, 10 mg/mL aprotinin, 10 mg/ mL leupeptin, 0.5 mM phenylmethylsulphonyl¯uoride). Following a 15 min incubation on ice, cells were lysed with 20 passages through a 25 gauge needle, and NaCl was added to a ®nal concentration of 0.1 M. Following a brief centrifugation, the supernatant was loaded on an SW60Ti Beckman swinging bucket rotor and ultracentrifuged at 100 000 g at 48C for 30 min. The supernatant represented the soluble cytosolic fraction (S-100), while the pellet was resuspended in lysis buer A/0.1 M NaCl and represented the particulate membrane fraction (P-100). Lysates were immunoprecipitated using the rat anti-pan-Ras antibody Y13-259 (Oncogene Science, Cambridge, MA, USA). Immunoprecipitated proteins were separated on a 15% SDS ± PAGE gel, and probed using an anti-pan-Ras antibody (OP40, Oncogene Science). Proteins were detected using alkaline phosphatase-conjugated secondary antibodies and Renaissance CDP-Star chemiluminescence (NEN/Dupont, Boston, MA, USA) as a doublet of processed and unprocessed Ras at 21 kDa (James et al., 1996) , Figure 4 .
Myelin Basic Protein (MBP) kinase assay
Plates of cells treated for 4 days with vehicle or drug were lysed using kinase lysis buer (25 mM HEPES pH 7.5, 0.3 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 20 mM b-glycerophosphate, 1% Triton X-100, 0.5 mM dithiothreitol, 20 mg/mL aprotinin, 20 mg/mL leupeptin, 1 mM phenylmethylsulphonyl uoride, 1 mM sodium orthovanadate). Protein concentration was determined using the bicinchoninic acid method. One hundred and ®fty micrograms of protein were immunoprecipitated overnight with protein A sepharose beads and 35 mL of anti-MAPK/ERK2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), which preferentially recognizes the ERK2 MAPK isoform, but also immunoprecipitates ERK1.
Immunoprecipitates were washed once with kinase lysis buer, three times with 1% NP40 in PBS/2 mM sodium orthovanadate, and once with 100 mM Tris.HCl (pH 7.5)/ 0.5 M LiCl in water. Lysates were ®nally washed once with kinase reaction buer (12.5 mM MOPS pH 7.5, 12.5 mM bglycerophosphate, 7.5 mM MgCl 2 , 0.5 mM EGTA, 0.5 mM NaF, 0.5 M sodium orthovanadate). Following this ®nal wash, immunoprecipitates were incubated for 1 h at 308C with 50 mL kinase reaction buer supplemented with 1.5 mg/ mL bovine Myelin Basic Protein (MBP; Sigma Chemical Company, St. Louis, MO, USA), 2 mM cold ATP, and 10 mCi/mL [g-32 P]ATP (NEN/Dupont, Boston, MA, USA; speci®c activity 3000 Ci/mmol). The kinase reaction was terminated by adding 25 mL of 36 sample buer (187.5 mM Tris-HCl pH 6.8, 6% w/v SDS, 30% glycerol, 150 mM DTT, 0.1% w/v bromophenol blue), samples boiled for 5 min at 1008C, and loaded on a 15% SDS ± PAGE gel. MBP was identi®ed as a 17 kDa protein by Coomassie blue staining, and kinase activity quanti®ed on a STORM PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). Kinase activity was normalized to MBP kinase activity in serum-starved HER14 cells (NIH3T3 ®broblasts transfected to express wild type human EGF-R), while HER14 cells stimulated with EGF for 5 min provided a positive control in each experiment, Figure 5 .
Cell cycle analysis and BrdU incorporation assay
The eect of L-744,832 on cell cycle progression was determined through FACS analysis of propidium iodide stained U87 and U373 cells. These two cell lines were examined due to their known p53 status: U87 cells are known to be wild type for p53, while U373 cells carry a point mutations at codon 273 (Gomez-Manzano et al., 1996) . All cells were treated with drug or vehicle for 3 days prior to ®xation with cold 70% ethanol. Fixed cells were treated with DNase-free RNase (Boehringer Mannheim) prior to staining with propidium iodide (50 mg/mL). Stained cells were promptly analysed on a Coulter Epics XL-MCL FACS workstation. Raw FACs data was imported into ModFit LT version 2 (Verity Software) for determination of the proportion of cells in the G 0 /G 1 and G 2 /M fractions of the cell cycle. All experiments were performed twice in duplicate, Figure 6 . The proportion of cells in S phase of the cell cycle was determined through immunocytochemistry for incorporated BrdU. U87 and U373 cells were plated onto poly-L-lysine (0.01%, Sigma) coated Lab-Tek Chamber Slide (Nunc Inc., Naperville, IL, USA), and treated for 3 days with drug or vehicle. Cells were incubated with 3 mg/mL BrdU in fresh DMEM at 378C for 60 min, prior to ®xation with cold absolute methanol. DNA in the ®xed cells was denatured by incubating slides in 2 M HCl for 60 min at 378C, and the acid subsequently neutralized with 0.1 M borate buer pH 8.5. A monoclonal mouse anti-BrdU antibody (Boehringer Mannheim) was used at 1 : 20 dilution, and detection carried out using the avidinbiotin complex (ABC) method (VectaStain Elite, Vector Laboratories, Burlingame, CA, USA). Nuclei were counterstained with hematoxylin. The fraction of nuclei staining positive for BrdU was determined at high power. At least ten ®elds were counted for each well, and all experiments were performed in triplicate, Figure 6 . Groups were compared using Factorial Analysis of Variance (ANOVA), and P values were obtained following application of Fisher's Protected Least Signi®cant Dierence post-hoc procedure to the data. A P value 50.05 following this procedure is considered signi®cant. These analyses were completed using StatView 5.0 for the Macintosh (SAS Institute, Cary, NC, USA).
Determination of apoptotic index using TUNEL assay
The rate of apoptosis in U87 and U373 cells was determined following 3 days of treatment with 20 or 50 mM L-744,832. Cells were plated on poly-L-lysine coated Lab-Tek Chamber Slides prior to drug treatment. Cells were ®xed using fresh 4% paraformaldehyde, and apoptotic nuclei were labelled using the Terminal deoxynucleotidyl transferase-mediated dUTP Nick End Labelling (TUNEL) assay (Gavrieli et al., 1992) . Detection was performed according to the manufacturer's suggestions (In Situ Cell Death Detection kit ± POD, Boehringer Mannheim). Cells were counterstained with hematoxylin. Apoptotic nuclei were identi®ed both by their staining and by their morphologic appearance. The fraction of apoptotic nuclei in the sample was determined in at least ten high power ®elds, and the experiment was carried out twice in duplicate, Figure 7 .
Western blots
Plates of cells treated for 4 days with vehicle or drug were lysed in modi®ed RIPA lysis buer (10 mM sodium phosphate pH 7.0, 1% NP40, 1% deoxycholate, 0.1% SDS, 2 mM EDTA, 150 mM sodium chloride, 50 mM sodium¯uoride, 10 mg/mL aprotinin, 10 mg/mL leupeptin, 0.1 mM phenylemethylsulphonyl¯uoride, 0.2 mM sodium orthovanadate). Protein concentrations were determined using the bicinchoninic acid method (Pierce Chemical Company, Rockford, IL, USA). Thirty micrograms of total protein were separated in 12.5% SDS ± PAGE gels, and transferred to PolyScreen PVDF membranes (NEN Research Products/DuPont, Boston, MA, USA) using a semi-dry transfer apparatus (Bio-Rad, Hercules, CA, USA). Antibodies used were as follows: Bax (rabbit polyclonal, Upstate Biotechnology [UBI], Lake Placid, NY, USA), Bak (rabbit polyclonal, UBI), Bcl-X L (rabbit polyclonal, Transduc-tion Laboratories, Lexington, KY, USA), Bcl-2 (monoclonal mouse, clone 124, UBI), p53 (monoclonal mouse, clone DO-7, DAKO, Carpinteria, CA, USA), pRB (monoclonal mouse, clone G3-245, PharMingen, San Diego, CA, USA), p21 WAF1/CIP1 (monoclonal mouse, clone SX118, PharMingen), b-actin (monoclonal mouse, clone AC-15, Sigma). Proteins were detected using alkaline-phosphatase-conjugated secondary antibodies and Renaissance CDP-Star chemiluminescence (NEN/Dupont, Boston, MA, USA), Figure 3 .
Immunocytochemistry for GFAP
To assess the eect of L-744,832 on the morphological characteristics of U87 and U373 cells, immunocytochemistry was performed for Glial Fibrillary Acidic Protein (GFAP). Cells were plated on poly-L-lysine-coated Lab-Tek Chamber Slides, and treated with drug or vehicle for 3 days. Cells were ®xed using absolute cold methanol and GFAP detected using a polyclonal rabbit anti-cow GFAP antibody at 1 : 4000 dilution (DAKO, Carpinteria, CA, USA). Detection was carried out using the ABC reagent, Figure 3 .
Determination of VEGF in conditioned medium using ELISA assay U373 cells were plated in 24-well multiwell plates at a density of 25 000 cells per well. Cells were treated with various concentrations of L-744,832 or 0.1% methanol for 3 days. Drug was replenished following 3 days of treatment, and cells either incubated for a further 24 h under normoxia, or exposed to hypoxic conditions for 24 h, as below. Conditioned medium was harvested from each well, and levels of VEGF determined using an ELISA kit (R&D Systems, Minneapolis, MN, USA). Cell counts in all wells were performed using a hemocytometer to enable normalization of VEGF levels to cell counts, Figure 9a ± b.
Metabolic labelling studies
We con®rmed the eect of L-744,832 in reducing VEGF secretion through metabolic labelling of U373 cells. Cells were initially treated with 20 mM L-744,832 for 3 days. Medium was then changed to labelling medium (90% methionine-free DMEM, 10% regular DMEM, 2 mM Lglutamine, 25 mM HEPES pH 7.4), and cells incubated in labelling medium for 1 h at 378C.
35
S-methionine was then added to the medium (250 mCi in 5 mL medium per 100 mm diameter plate), and incubations carried out under hypoxic conditions as below for 18 h. Parallel plates were incubated with vehicle only. Following hypoxic treatment, conditioned medium was removed from the plates and VEGF proteins immunoprecipitated using 1 mg of a rabbit polyclonal anti-VEGF antibody which recognizes all known isoforms of mouse, rat, and human VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Following overnight immunoprecipitation, immunoprecipitates were washed with HNTG (20 mM HEPES pH 7, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol), and boiled in the presence of 26 sample buer (125 mM Tris-HCl pH 6.8, 4% w/v SDS, 20% glycerol, 100 mM DTT, 0.1% w/v bromophenol blue). Proteins were separated on a 15% SDS ± PAGE gel, the gel dried, and exposed to ®lm (Kodak) for 10 days. The speci®city of the antigen-antibody interactions were con®rmed using a competition peptide (Santa Cruz Biotechnology), as demonstrated in Figure 9d , lane 3.
Northern blot analysis for Vascular Endothelial Growth Factor (VEGF)
Cells were plated on 100 mm diameter tissue culture plates, and treated with varying concentrations of L-744,832 or vehicle for 3 days. Medium and drug were replenished at this time, and plates were grown for a further 24 h under either normoxic or hypoxic conditions. Cells to be grown under hypoxic conditions were placed in a sealed chamber, and hypoxia was induced using BBL GasPak Plus anaerobic system envelopes were palladium catalyst (Becton Dickinson, Cockeysville, MD, USA). Hypoxic conditions were monitored using BBL Dry Anaerobic Indicator Strips (Becton Dickinson), and con®rmed using an oxygen gas sensor (demonstrating O 2 content in the chamber at 0.1%). All incubations were carried out at 378C. Following 24 h of hypoxic or normoxic growth, total RNA was extracted using RNeasy columns (QIAGEN). Eight micrograms of total RNA was separated in an agarose-formaldehyde gel, and transferred to Hybond neutral nylon (Amersham Pharmacia) by capillary action. Membranes were pre-hybridized using ExpressHyb hybridization solution (CLONTECH, Palo Alto, CA, USA) at 688C. A VEGF cDNA probe, which recognizes all four VEGF mRNA isoforms (gift of Brygida Berse, Beth Israel Hospital, Boston, MA, USA) was radiolabelled with a-32 P-dCTP (3000 Ci/mmol) using the T7 QuickPrime Kit (Amersham Pharmacia). The probe was puri®ed through a Sephadex G-50 column, and the membrane hybridized in ExpressHyb solution according to the manufacturer's recommendations. The membranes were washed in sequential steps with 26 SSC/0.05% SDS and 0.16 SSC/0.1% SDS, and exposed to ®lm (Kodak), Figure 9d .
